P32/98 hemifumarate 

P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model^[1][2][3].

GLP-1 acts function of stimulation of glucose dependent insulin secretion and induction of satiety feelings, and DPPIV is the major renal catabolic pathway for GLP-1 in vivo^[2].
P32/98 hemifumarate, together with 200 pM GLP-1, (10 μM; 3 h) shows no significant inhibition of sodium re-absorption in porcine proximal tubular cells^[2].
P32/98 hemifumarate (10 μM; 96 h) does not influence the mRNA expression of GLP-1R, DPPIV, Na⁺/H⁺ exchanger isoform 3 (NHE3), sodium-dependent glucose transporter slc5a1, slc5a2 (SGLT1, 2)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P32/98 hemifumarate (25 mg/kg; i.g.; once daily) long-time treatment significantly improves the glucose tolerance in Zucker diabetic fatty rats, a model of IGT (impaired glucose tolerance)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

260.36

C₉H₁₈N₂OS.1/2C₄H₄O₄

251572-86-8

CC[C@H](C)[C@H](N)C(N1CSCC1)=O.O=C(O)/C=C/C(O)=O.[1/2]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Augstein P, et al. Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. Diabetes Obes Metab. 2008;10(10):850-861.  [Content Brief]

  [2]. Schlatter P, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007 Jun 7;141(1-3):120-8.   [Content Brief]

  [3]. Wargent E, et al. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes Metab. 2005;7(2):170-181.  [Content Brief]